Objectives

- To review background of pediatric hypertension
- To learn about ambulatory BP monitoring
- To discuss the HTN Best Practice Alert protocol at KP
- To review definitions of acute kidney injury and chronic kidney disease

Background

- NHANES (National Health and Nutrition Examination Surveys) data from 2003–2006:
  - 13.0% of the boys aged 8–17 years and 5.7% of the girls aged 8–17 years were classified as having pre-hypertension
  - 2.0% of the boys aged 8–17 and 3.4% of the girls aged 8–17 were classified as having hypertension
  - Non-Hispanic black girls were more likely to be classified as having pre-hypertension when compared with non-Hispanic white girls (odds ratio=1.53)

MEASUREMENT OF BP IN CHILDREN

- Children > 3 years old who are seen in a medical setting should have their BP measured.
- The preferred method of BP measurement is auscultation.
- Correct measurement requires a cuff that is appropriate to the size of the child’s upper arm.
- Elevated BP must be confirmed on 3 occasions before characterizing a child as having HTN.
- Measures obtained by oscillometric devices that exceed the 90% should be repeated by auscultation.

< 3 YEARS OLD

<table>
<thead>
<tr>
<th>TABLE I. Conditions Under Which Children &lt;3 Years Old Should Have BP Measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of prematurity, very low birth weight, or other neonatal complications requiring intensive care</td>
</tr>
<tr>
<td>Congenital heart disease (repaired or nonrepaired)</td>
</tr>
<tr>
<td>Recurrent urinary tract infections, hematuria, or proteinuria</td>
</tr>
<tr>
<td>Known renal disease or uric acid abnormalities</td>
</tr>
<tr>
<td>Family history of congenital renal disease</td>
</tr>
<tr>
<td>Solid-organ transplant</td>
</tr>
<tr>
<td>Malignancy or bone marrow transplant</td>
</tr>
<tr>
<td>Treatment with drugs known to raise BP</td>
</tr>
<tr>
<td>Other systemic illnesses associated with hypertension (neonatal infections, tuberous sclerosis, etc.)</td>
</tr>
<tr>
<td>Evidence of elevated intracranial pressure</td>
</tr>
</tbody>
</table>

BP measurement

- Place stethoscope over the brachial artery pulse, proximal and medial to the cubital fossa, and below the bottom edge of the cuff (ie, ~2cm above the cubital fossa)
- Child should have avoided stimulant drugs or foods
- Child should have been sitting quietly for 5 minutes with his or her back supported, feet on the floor and right arm supported, cubital fossa at heart level
BP CUFF

- Bladder width >40% of arm circumference at a point between the olecranon and the acromion.
- Cuff bladder length should over 80-100% of the circumference of the arm.
- Standard cuff dimensions for children should be adopted.
Pediatric Hypertension: Definition (revised in 2017)

- Normal BP: <90th percentile
- Elevated BP: >90th or 120/80 whichever is lower
- Stage 1 HTN: >90th or 120/80
- Stage 2 HTN: >95th or 12 mm Hg or 130/80-139/89 whichever is lower

Using HealthConnect

- To determine patient’s BP %ile based on gender, height and age, type in smartphrase .BPFAW95
- To look up past blood pressure values, type in .lastbp3 or .lastbp/#
At Peds Nephrology Consult

- If patient is asymptomatic, we will recommended ABPM to rule out white coat hypertension before proceeding with additional work up
- If ABPM confirms HTN, we will obtain additional work up, including renal ultrasound, laboratory tests and echocardiogram to rule out LVH
- We will determine if patient needs pharmacologic agent vs. continuing lifestyle management based on ABPM result

What is ABPM?
Ambulatory BP Monitoring (ABPM)

- Portable automated BP device that takes reading every 15-30 minutes when awake and every 30-60 min when asleep.
- BP follows a circadian pattern, falling by 13-20% below daytime levels during sleep at night (“nocturnal dipping”).
- BP load in children is defined as percentage of BP > 95% on ABPM.
- High BP load and the absence of nocturnal dipping have been associated with end-organ damage in both adults and children.


Ambulatory BP Monitoring (ABPM)

ABPM is used for evaluation of:

- White coat hypertension
- Hypotensive symptoms
- Masked hypertension
- Effectiveness of antihypertensive treatment
- BP pattern in patients with chronic kidney disease, diabetes, autonomic dysfunction or episodic hypertension

Patient has true hypertension if…

- > 25% of BP loads exceeds 95%ile or greater
- < 10% dip during nocturnal BP measurements
Etiology of HTN

- Newborn
- Toddler
- Older kids
- Adolescents

ETIOLOGY BY AGE

- Newborn
  - Renal artery thrombosis
  - Renal vein thrombosis
  - Congenital renal malformation
  - Coarctation
  - Renal artery stenosis
  - Bronchopulmonary dysplasia
- Infancy to 6 yr
  - Renal parenchymal disease
  - Renal artery stenosis
  - Coarctation
  - Medication
  - Endocrine
- 6-10 yr
  - Renal parenchymal disease
  - Renal artery stenosis
  - Essential hypertension
  - Endocrine causes
- Adolescence
  - Essential HTN
  - White-coat HTN
  - Renal parenchymal disease
  - Substance abuse
  - Endocrine causes

History

- History of hypertension
- Stopped using antihypertensive medications?
- Umbilical vessel catheterization
- Genitourinary abnormalities
- Recent head injury
- Medication history (steroids, OCP's, tacrolimus)
- Substance abuse
- Vision changes
- Headaches
- Confusion
- Somnolence
- Seizures
- Chest pain
- Respiratory difficulties
- Nausea or vomiting
- Oliguria
Physical Exam

- Vital signs and 4 limb blood pressures
- Fundoscopic exam – papilledema, hemorrhages
- Full neurologic exam
- Lungs – pulmonary edema
- CV – gallops
- Abdomen – hepatomegaly
- Extremities – edema, femoral pulses

Turner Syndrome

- Short stature
- Low hairline
- Shield-shaped thorax
- Widely spaced nipples
- Shortened metacarpals
- Small finger nails
- Brown spots (nevus)
- No menstruation

Coarctation
### Tuberous Sclerosis

<table>
<thead>
<tr>
<th>Location</th>
<th>Lesion Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head</td>
<td>Angiofibroma</td>
</tr>
<tr>
<td>Finger</td>
<td>Periungual fibroma</td>
</tr>
<tr>
<td>Skin</td>
<td>Hypomelanotic macules</td>
</tr>
<tr>
<td>Skin</td>
<td>Shagreen patch</td>
</tr>
<tr>
<td>Brain</td>
<td>Cortical Tuber</td>
</tr>
<tr>
<td>Brain</td>
<td>Subependymal nodule</td>
</tr>
<tr>
<td>Brain</td>
<td>Astrocytoma</td>
</tr>
<tr>
<td>Eye</td>
<td>Retinal hamartoma</td>
</tr>
<tr>
<td>Heart</td>
<td>Rhabdomyoma</td>
</tr>
<tr>
<td>Lungs</td>
<td>Lymphangioleiomyomatosis</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Angiomyolipoma</td>
</tr>
</tbody>
</table>

### COMPLICATIONS OF HTN

- **CNS**
  - Hypertensive Encephalopathy
  - Retinopathy
- **Cardiac**
  - LVH
- **Renal**
  - Hypertensive nephropathy
Lifestyle modification:
- Dietary changes – sodium restriction, increased fruits and vegetable and fiber
- Increase physical activity
- Weight loss in the obese

Pharmacologic agents
- If mild, may wait for work up
- If severe, control with antihypertensives while undergoing work up
Sodium restriction in HTN

- Sodium reduction in children and adolescents has been associated with BP reduction in the range of 1-3 mm Hg.
- Daily sodium recommendations is only 1.2 g/day for 4- to 8-year-olds and 1.5 g/day for older children.

Exercise and Obesity

- Regular aerobic activities (30-60 minutes of moderate physical activity on most days) and limitation of sedentary activities to <2 hours per day.
- With the exception of power lifting, resistance training is also helpful.
- Competitive sports participation should be limited only in the presence of uncontrolled stage 2 hypertension.

TREATMENT

<table>
<thead>
<tr>
<th>TABLE 6: Indications for Antihypertensive Drug Therapy in Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic hypertension</td>
</tr>
<tr>
<td>Secondary hypertension</td>
</tr>
<tr>
<td>Hypertensive target-organ damage</td>
</tr>
<tr>
<td>Diabetes (types 1 and 2)</td>
</tr>
<tr>
<td>Persistent hypertension despite nonpharmacologic measures</td>
</tr>
</tbody>
</table>
ACE-I/ARBs

Note: ACE-I causes coughing. Avoid in single kidney with renal artery stenosis and pregnancy.

β-blockers

Notes: Causes fatigue and exercise intolerance. Labetalol is both β- and α-blocker, so contraindicated in asthmatics and congestive heart failure due to negative inotropic effects. Use with caution in diabetics as it may mask hypoglycemia.

Ca++ Channel Blockers

Note: side effects include edema and gingival hyperplasia.
**Central α-agonist**

<table>
<thead>
<tr>
<th>Central α-agonist</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonidine (Catapres)</td>
<td>10–30 μg/kg/day: Q8–24h</td>
</tr>
<tr>
<td>Maximum 2400 μg/day</td>
<td></td>
</tr>
<tr>
<td>Clonidine transdermal patch (Catapres TTS)</td>
<td>TTS-I–II weekly</td>
</tr>
</tbody>
</table>

Note: causes significant fatigue.

**Diuretics**

<table>
<thead>
<tr>
<th>Diuretics</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone (Aldactone, generic)</td>
<td>1–3.3 mg/kg/day: Q12h</td>
</tr>
<tr>
<td>Maximum 100 mg/day</td>
<td></td>
</tr>
<tr>
<td>Chlorothiazide (Diuril, generic)</td>
<td>10–20 mg/kg/day, given once daily</td>
</tr>
<tr>
<td>Maximum 1000 mg/day</td>
<td></td>
</tr>
<tr>
<td>Furosemide (Lasix, generic)</td>
<td>0.5–6 mg/kg/dose: Q12h</td>
</tr>
<tr>
<td>Maximum 800 mg/day</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide (Hyduret, Omcor, Microzide, Edecrin, generic)</td>
<td>1–3 mg/kg/day, given once daily</td>
</tr>
<tr>
<td>Maximum 50 mg/day</td>
<td></td>
</tr>
</tbody>
</table>

Note: may cause dehydration, avoid in athletes.

**Others**

<table>
<thead>
<tr>
<th>Peripheral α-antagonist</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prazosin (Minipress)</td>
<td>5–100 μg/kg/dose: Q8–12h</td>
</tr>
<tr>
<td>Transdermally</td>
<td></td>
</tr>
<tr>
<td>Hydralazine (Apresoline, generic)</td>
<td>0.75–7.5 mg/kg/day: Q6h</td>
</tr>
<tr>
<td>Maximum 200 mg/day</td>
<td></td>
</tr>
<tr>
<td>Minoxidil (Lanette, generic)</td>
<td>0.05–0.5 mg/kg/day: Q3–12h</td>
</tr>
<tr>
<td>Maximum 50 mg/day</td>
<td></td>
</tr>
<tr>
<td>Maximum 100 mg/day</td>
<td></td>
</tr>
</tbody>
</table>

Note: Hydralazine may cause flushing, tachycardia, hypotension, and lupus-like syndrome.

Minoxidil causes hypertrichosis.
FOLLOW-UP

- After initiation drug therapy:
  - Every 2-4 weeks follow-up visit until BP control has been achieved.
  - Then q3-4 months thereafter.
  - Home BP monitoring and assessment for medication side-effects are important.
  - Periodic reassessment for hypertensive target-organ damage and laboratory monitoring should be performed.

What if ABPM is normal?

- White coat hypertension
What if ABPM is normal?

- White coat hypertension
- Is follow up needed?

Ambulatory BP/White Coat HTN

- In a group of 126 children, ABPM detected 58 subjects (46%) with white-coat HTN, 62 (49%) with stage 1 HTN and 6 (5%) with stage 2 HTN.
- In adults, white coat HTN may not be a benign condition (increased LVH and risks for sustained HTN).
- Limited data in children, but there may be a role in monitoring patients with white coat HTN.

Prehypertension and White Coat HTN

- Recent debate calling for earlier intervention for HTN, especially those with prehypertension and WCH\(^1\)
- Analysis of tracking studies confirms that high BP in the young predicts future high BP\(^2\)
- Data showing reduced GFR and proteinuria in children with prehyptertensions\(^3\)

References:


White coat hypertension

- Annual follow up with pediatric nephrologist or PCP recommended
- Reinforce lifestyle modification
- Relaxation techniques
- Annual ABPM may be of value in patients with WCH

Summary of HTN BPA

- Automatic alert for BP > 95% and reinforces follow up BP measurements
- If BP > 95% in children < 12 or > 130/80 in 13-17 years old on 3 occasions (3rd BP confirmed on auscultation), send pediatric nephrology referral/Dr. Advice
- If patient is symptomatic or history suggests acute pathology (glomerulonephritis, renal failure, end organ damage i.e. encephalopathy…), contact pediatric nephrology immediately

CASE 2

A 10 month old infant is seen in the ED with 3 day history of low grade fever, vomiting and diarrhea. The physical examination reveals a severely dehydrated infant. Wt 8.9 kg. Temp 101, HR 168/min, RR 33/min and BP 68/40. Patient's creatinine is 2.8.

What is your Dx and what should be further management?
Etiology of ARF

- Pre Renal
- Intrinsic Renal
- Post Renal

Work up

\[ \text{FE Na} = \frac{U \text{Na}}{P \text{Na}} \times \frac{P \text{Cr}}{U \text{Cr}} \times 100 \]

ARF ETIOLOGY

PRE RENAL : DEHYDRATION, HEART FAILURE

POST RENAL : OBSTRUCTION

INTRINSIC RENAL : TUBULAR, GLOMERULAR

VASCULAR, INTERSTITIAL
CLINICAL FEATURES OF ARF
1. Reduced Urine Output
2. Dehydration, Hypotension or Volume Overload, Hypertension, CHF
3. Uremia, Malaise, Nausea
4. Arrhythmia's with Hyperkalemia

Parameters to Monitor for Conservative ARF Management
- Strict I & O
- Daily, sometimes twice daily weights
- Q4 to 8H Serum Electrolytes, Cr/BUN Daily Serum Ca, Phosphate, Albumin
- May need to measure volume of urine or other drainage fluids for proper replacement
- ? of Central Venous Catheter for CVP

Prevention of ARF
1) Early Detection and Treating Cause
2) Fluid Challenge
   • 20 ml/kg Normal Saline
3) Furosemide or Mannitol
Management of ARF

1) Fluid Balance
2) Electrolyte Na, K, HCO₃
3) Nutrition
4) Use of Furosemide
5) Renal dose medication
6) Dialysis: Peritoneal or Hemo

Daily Fluid Management in ARF

- For Insensible Losses: 30% of Normal Daily Fluid Intake or 400 ml/m²/day
- Replace Urinary or Other Losses*: ml for ml
  - Includes NG tube, other drains, diarrhea, vomiting, 3rd space fluids.
  - Decrease for medication administration

Renal Replacement Therapy in ARF

- Peritoneal Dialysis
- Hemodialysis
- CVVH, CVVHD
- Renal Transplantation
Case 3

- Patient is a 8 year old male ex 25 weeker. He has been doing well since NICU discharge for prematurity, and was recently found to have elevated creatinine of 1.2 during a clinic visit to evaluate for short stature.

Case

- Does this patient have chronic kidney disease (CKD)?
- What defines CKD?
- How to determine his GFR?
- What complications need to be addressed?

CKD Staging

<table>
<thead>
<tr>
<th>Stage</th>
<th>GFR (ml/min/1.73 m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&gt;90</td>
</tr>
<tr>
<td>2</td>
<td>60-89</td>
</tr>
<tr>
<td>3</td>
<td>30-59</td>
</tr>
<tr>
<td>4</td>
<td>15-30</td>
</tr>
<tr>
<td>5</td>
<td>&lt;15 or dialysis</td>
</tr>
</tbody>
</table>
GLOMERULAR FILTRATION RATE

- **GFR** = volume of plasma ultrafiltrate presented to the nephrons per unit time in the process of urine formation.

GFR can be measured in 2 ways:

1. Directly measuring the **clearance** of an ideal filtration marker.

2. Using **equations** to estimate GFR.

ESTIMATING EQUATIONS

1. Cockcroft-Gault estimate
   - > 12 years old

2. Modification of Diet in Renal Disease (MDRD)
   - Adults with GFR < 60

3. Schwartz formula
   - Pediatric population
**SCHWARTZ FORMULA**

- GFR = (K * H) / S\(_{cr}\)
- GFR = ml/min/1.73m\(^2\)
- K = constant determined by Schwartz et al.
  - K = 0.413
- H = height in cm
- S\(_{cr}\) = serum creatinine in mg/deciliter.

**Complications of CKD**

- Anemia
- Blood pressure elevation
- Ca/phos: Renal Osteodystrophy
- Dialysis/transplant
- Electrolyte imbalance
- Fluid/nutrition
- Growth
- Hematological disorder
- Infection/immunization

**Anemia**

**Causes**

- Insufficient erythropoietin production
- Iron deficiency (poor nutritional intake)

**Goal**

- Hematocrit 33-36% and hemoglobin 11-12 g/dL for children with CKD
  - Epogen 30-300 units/kg/week (initial) and 60-600 units/kg/week (maintenance)
  - 2-3mg/kg/day of oral elemental iron
  - IV dextran/ferrlicit if iron saturation < 25%
Blood Pressure Elevation

- Renin-angiotensin system activation
  - ACEI (lisinopril, enalapril)
  - ARB (losartan)

- Fluid retention
  - Diuretics (furosemide, hydrochlorothiazide, spironolactone)
  - Salt restriction (< 2 gram/day, no added salt)

Ca/Phos: Renal Osteodystrophy

- Hypocalcemia
  - Decreased vitamin D 1,25 production
  - Complex with excess serum phosphorus

- Hyperphosphatemia
  - Decreased renal excretion

- Hyperparathyroidism
  - Caused by low serum calcium and vitamin D 1, 25
  - Weakens bone and cause fracture/deformity
Dialysis

Indications:
- Acidosis
- Electrolyte disorder
- Ingestion/intoxication
- Overload
- Uremia

Peritoneal Dialysis

Hemodialysis
Electrolyte Disorder

- Acidosis
  - Decreased renal bicarbonate reabsorption
  - Reduction of renal ammonia synthesis
  - Acidosis leads to protein degradation and efflux of calcium from bone
- Hyperkalemia
  - 90% of daily intake of potassium excretion occurs in the distal tubules
  - Less nephrons=less tubules=less potassium excretion=hyperkalemia

Fluid/Nutrition

- Low calcium, phosphorus, potassium
- Protein reduction 0.8-1.1g/kg/day in adults
Growth Failure

Causes

◼ Poor nutrition
◼ Anemia
◼ Acid-base imbalance
◼ Renal osteodystrophy
◼ GH and IGF-I resistance
  ◦ Reduced GH receptors
  ◦ Upregulations of GH inhibitors (i.e. SOCS)
  ◦ Elevated IGF-binding proteins

Hematologic Disorder

◼ Hypercoagulable state in patients with SLE (anti-phospholipid syndrome) or nephrotic syndrome

◼ Renal patients are often on aspirin or coumadin therapy

Infection/Immunization

◼ All children with CKD should receive all routine immunizations including influenza and Prevnar
◼ Dialysis affects the immune system and can remove hepatitis B antibodies, so titers are measured periodically
◼ Live vaccines (Varicella and MMR) prior to renal transplant
Returning to our case

- Patient is a 8 year old male ex 25 weeker with multiple post-natal complications, including: "Anemia of prematurity status post Epogen treatment, Rickets of prematurity with three long bone fractures, Retinopathy of prematurity, and Chronic lung disease". He has been doing well since NICU discharge, and was recently found to have elevated creatinine of 1.2 during a clinic visit to evaluate for short stature.

Case

- Does this patient have chronic kidney disease (CKD)?
- What defines CKD?
- How to determine his GFR?
- What complications need to be addressed?

Case

- Anemia: Hg = 14, Hct = 40.8, iron sat 40%
- BP: 112/49
- Ca/phos: Phos 4.9 Ca 10.3
  - Vitamin D 25: 32 (normal)
  - PTH 62 (normal)
- Dialysis/transplant: NA
- Electrolyte: K 4.8, CO₂ 27
- Fluid/nutrition: poor weight gain
- Growth: <5% weight and height
  - Maximize nutrition and start growth hormone therapy
- Hematological disorder: NA
- Infection/immunization: NA